BioCentury | Mar 24, 2014
Clinical News

THR1442: Phase II data

A 96-week, double-blind, international Phase II trial in 288 Type II diabetics inadequately controlled by diet and exercise and up to 1 oral anti-diabetic agent showed that oral THR1442 met the primary endpoint of reducing...
BioCentury | Mar 17, 2014
Clinical News

Theracos' SGLT2 inhibitor meets in Phase II trial

Theracos Inc. (Marlborough, Mass.) said oral THR1442 met the primary endpoint of reducing HbA1c from baseline to week 24 vs. placebo in a Phase II trial to treat Type II diabetes (p<0.0001). THR1442 also met...
Items per page:
1 - 2 of 2